⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24655977 | 0.79 | — | — | |
| SCHEMBL3973873 | 0.78 | LMNA (0.45) | — | |
| SCHEMBL5002708 | 0.78 | — | — | |
| SCHEMBL18959706 | 0.75 | CHRM2 (0.39) | — | |
| SCHEMBL10794918 | 0.75 | CHRM2 (0.46) | — | |
| SCHEMBL7616550 | 0.75 | CHRM2 (0.46) | — | |
| SCHEMBL9250509 | 0.74 | CHRM2 (0.42) | — | |
| SCHEMBL35893 | 0.74 | — | — | |
| SCHEMBL21016655 | 0.74 | — | — | |
| SCHEMBL6561953 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358659-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-23 | — | — | US | claimed |
| JP-2004509604-A | — | — | 2004-04-02 | — | — | JP | claimed |
| JP-2003520042-A | — | — | 2003-07-02 | — | — | JP | claimed |
| EP-1263765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-11 | — | — | EP | claimed |
| EP-1250157-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001072765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001052902-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| CN-113736782-B | Compositions and methods for inhibiting TMPRSS6 gene expression | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-113057959-B | Ketohexokinase (KHK) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-112313335-B | Renin (AGT) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302525-A | Complement Factor B (CFB) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118265791-A | Spherical nucleic acids for cGAS-STING and STAT3 pathway modulation for immunotherapeutic treatment of cancer | 西北大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-118265786-A | Microtubule-associated protein Tau (MAPT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2001000808-A1 | ANTISENSE MODULATION OF SHIP-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000651-A1 | ANTISENSE MODULATION OF G-ALPHA-i3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000074687-A1 | ANTISENSE MODULATION OF B7 PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000070091-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF HUMAN PROTEIN KINASE C-δ EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000061150-A1 | ANTISENSE MODULATION OF FAS MEDIATED SIGNALING | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000061602-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999011820-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND QUANTITATION OF DELETION SEQUENCE OLIGONUCLEOTIDES IN SYNTHETIC OLIGONUCLEOTIDE PREPARATIONS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |